PCR 기술 시장 : 기술별, 제품별, 용도별, 최종사용자별, 지역별 - 세계 예측(-2031년)

The PCR technologies market is projected to reach USD 21,430 million by 2031, up from USD 15,550 million in 2026, at a CAGR of 6.6% during 2026-2031.

The PCR technologies market is evolving toward higher efficiency, accuracy, sensitivity, and versatility, driven by advances in sophisticated instrumentation and high-fidelity enzymes. Real-time PCR (qPCR) enables real-time monitoring and quantitative analysis, while RT-PCR supports RNA analysis, gene expression studies, and viral detection. Digital PCR (dPCR) is gaining importance for applications requiring highly precise and sensitive absolute quantification, further broadening PCR's applications across research and diagnostics.

"qPCR to account for largest market share in 2025."

qPCR is expected to hold the largest share of the PCR technologies market due to its established use in diagnostics and research, where precise quantification is required. By combining PCR amplification with real-time monitoring using fluorescent dyes or probes, qPCR enables quantitative analysis of target DNA at each cycle. Its broad utility and established role in molecular diagnostics and research support its widespread adoption.

"Diagnostic laboratories to hold largest share in the market."

Diagnostic laboratories are expected to remain the largest end users of PCR technologies, driven by the growing need for rapid, sensitive, and accurate molecular testing. PCR is widely used for infectious disease detection, genetic testing, oncology, and disease monitoring. Rising testing volumes and demand for high-throughput workflows further support adoption. The shift toward automated, standardized, and integrated molecular testing systems is also strengthening PCR utilization in diagnostic laboratories.

North America is expected to retain the largest share of the PCR technologies market in 2026, supported by advanced healthcare infrastructure, strong adoption of molecular diagnostics, and substantial investments in genomics, precision medicine, and life-science research. The region also benefits from major PCR technology providers and the widespread use of PCR in clinical diagnostics, infectious disease testing, oncology, and genetic testing. Strong research capabilities and ongoing development of advanced PCR platforms further reinforce North America's market leadership.

A breakdown of the primary participants referred to for this report is provided below:

• By Company Type: Tier 1-30%, Tier 2-42%, and Tier 3- 28%
• By Designation: C-level-- 10%, Director-level-14%, and Others-76%
• By Region: North America-40%, Europe-30%, Asia Pacific-22%, Rest of the World - 8%.

Prominent players in the PCR technologies market include F. Hoffman-La Roche Ltd. (Switzerland), Thermo Fisher Scientific, Inc. (US), Bio-Rad Laboratories, Inc. (US), QIAGEN (Germany), Sansure Biotech Inc. (China), Becton, Dickinson and Company (US), Analytik Jena AG (Germany), Takara Bio, Inc. (Japan), Agilent Technologies, Inc. (US), Standard Biotools (US), Danaher Corporation (US), Abbott Laboratories (US), Merck KGaA (Germany), Illumina, Inc. (US), Bioneer Corporation (South Korea), PerkinElmer Inc. (US), and Hologic Inc. (US).

Research Coverage

The research report examines the market by product, material end-users, and geography. This research covers factors that are driving market expansion, analyzes current industry prospects and challenges, and provides specifics on the competitive landscape, including market leaders and small and medium enterprises. This research also estimates the revenue of different market segments by considering five regions and micro-market analysis.

Reasons to Buy the Report

The report will provide market leaders and new entrants with valuable information on revenue estimates for the overall market and its subsegments. It will help stakeholders understand the competitive landscape, enabling them to position their businesses more effectively and develop appropriate go-to-market strategies. Additionally, the report offers insights into market dynamics, including key drivers, restraints, challenges, and opportunities.

This report provides insightful data on the following pointers:

• Market Penetration: In-depth coverage of product portfolios offered by the top players in the PCR technologies market
• Product Development/Innovation: In-depth coverage of product portfolios offered by the top players in the PCR technologies market
• Market Development: Insightful data on profitable developing areas
• Market Diversification: Details about recent developments and advancements in the PCR technologies market
• Competitive Assessment: Extensive assessment of the products, growth tactics, revenue projections, and market categories of the top competitors

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 SEGMENTS CONSIDERED
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

• 2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS
• 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
• 2.3 DISRUPTIVE TRENDS IN PCR TECHNOLOGIES MARKET
• 2.4 HIGH-GROWTH SEGMENTS

3 PREMIUM INSIGHTS

• 3.1 PCR TECHNOLOGIES MARKET OVERVIEW
• 3.2 PCR TECHNOLOGIES MARKET, BY REGION
• 3.3 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY COUNTRY AND PRODUCT
• 3.4 GEOGRAPHIC SNAPSHOT OF PCR TECHNOLOGIES MARKET

4 MARKET OVERVIEW

• 4.1 INTRODUCTION
• 4.2 MARKET DYNAMICS
  • 4.2.1 DRIVERS
    • 4.2.1.1 Laboratories Increasing outbreaks of infectious diseases/viral persistence
    • 4.2.1.2 Development of miniaturized and portable point-of-care testing devices
    • 4.2.1.3 High demand for technologically advanced molecular diagnostics
  • 4.2.2 RESTRAINTS
    • 4.2.2.1 Premium product pricing
    • 4.2.2.2 Dearth of skilled healthcare professionals
  • 4.2.3 OPPORTUNITIES
    • 4.2.3.1 Increased investments in laboratory infrastructure
    • 4.2.3.2 Rising number of applications in rare sequence detection
  • 4.2.4 CHALLENGES
    • 4.2.4.1 Technical limitations
    • 4.2.4.2 Increased pricing pressure on market players
• 4.3 UNMET NEEDS AND WHITE SPACES
• 4.4 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

• 5.1 PORTER'S FIVE FORCES ANALYSIS
  • 5.1.1 THREAT OF NEW ENTRANTS
  • 5.1.2 THREAT OF SUBSTITUTES
  • 5.1.3 BARGAINING POWER OF SUPPLIERS
  • 5.1.4 BARGAINING POWER OF BUYERS
  • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.2 MACROECONOMIC OUTLOOK
  • 5.2.1 INTRODUCTION
  • 5.2.2 MACROECONOMIC INDICATORS
  • 5.2.3 GDP TRENDS AND FORECAST
  • 5.2.4 TRENDS IN GLOBAL PCR TECHNOLOGIES MARKET
• 5.3 VALUE CHAIN ANALYSIS
  • 5.3.1 RESEARCH & DEVELOPMENT
  • 5.3.2 RAW MATERIAL PROCUREMENT AND MANUFACTURING
  • 5.3.3 DISTRIBUTION, MARKETING & SALES, AND POST-SALES SERVICES
• 5.4 ECOSYSTEM ANALYSIS
• 5.5 PRICING ANALYSIS
  • 5.5.1 INDICATIVE PRICING REAL-TIME PCR INSTRUMENTS, BY KEY PLAYER, 2025
  • 5.5.2 INDICATIVE PRICING OF PCR TECHNOLOGY-BASED PRODUCTS, BY REGION, 2023-2025
    • 5.5.2.1 North America
    • 5.5.2.2 Europe
    • 5.5.2.3 Asia Pacific
    • 5.5.2.4 Rest of the World
• 5.6 TRADE DATA ANALYSIS
  • 5.6.1 IMPORT DATA FOR HS CODE 3822
  • 5.6.2 EXPORT DATA (HS CODE 3822)
• 5.7 KEY CONFERENCES & EVENTS, 2026-2027
• 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.9 INVESTMENT AND FUNDING SCENARIO
• 5.10 CASE STUDY ANALYSIS
  • 5.10.1 MULTIPLEX DETECTION OF KRAS MUTATIONS IN CELL-FREE DNA USING DIGITAL PCR
  • 5.10.2 PCR-BASED IDENTIFICATION OF ACINETOBACTER BAUMANNII SUPPORTS TARGETED INFECTION MANAGEMENT
• 5.11 IMPACT OF US TARIFFS - PCR TECHNOLOGIES MARKET
  • 5.11.1 INTRODUCTION
  • 5.11.2 KEY TARIFF RATES
  • 5.11.3 PRICE IMPACT ANALYSIS
    • 5.11.3.1 Impact on countries/regions
    • 5.11.3.2 Impact on end-users

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACTS, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

• 6.1 KEY TECHNOLOGIES
  • 6.1.1 THERMAL CYCLERS
  • 6.1.2 REAL-TIME QUANTITATIVE PCR
  • 6.1.3 PORTABLE AND POINT-OF-CARE PCR
• 6.2 COMPLEMENTARY TECHNOLOGIES
  • 6.2.1 NEXT-GENERATION SEQUENCING
  • 6.2.2 MICROARRAYS
  • 6.2.3 LAB-ON-A-CHIP DEVICES
  • 6.2.4 ROBOTICS AND AUTOMATION
• 6.3 PATENT ANALYSIS
• 6.4 IMPACT OF AI/GEN AI ON PCR TECHNOLOGIES MARKET
  • 6.4.1 TOP USE CASES AND MARKET POTENTIAL
  • 6.4.2 BEST PRACTICES FOLLOWED BY COMPANIES IN PCR TECHNOLOGIES MARKET
  • 6.4.3 CASE STUDIES RELATED TO AI/GEN AI IMPLEMENTATION IN PCR TECHNOLOGIES MARKET
  • 6.4.4 INTERCONNECTED ECOSYSTEM AND IMPACT ON MARKET PLAYERS
  • 6.4.5 CLIENT'S READINESS TO ADOPT AI/GEN AI IN PCR TECHNOLOGIES MARKET
• 6.5 SUCCESS STORIES AND REAL-WORLD APPLICATIONS

7 CUSTOMER LANDSCAPE AND BUYER BEHAVIOR

• 7.1 DECISION-MAKING PROCESS
• 7.2 KEY STAKEHOLDERS IN BUYING PROCESS AND EVALUATION CRITERIA
  • 7.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 7.2.2 KEY BUYING CRITERIA
• 7.3 ADOPTION BARRIERS AND INTERNAL CHALLENGES
• 7.4 UNMET NEEDS OF VARIOUS APPLICATIONS
• 7.5 REGULATORY LANDSCAPE
  • 7.5.1 REGULATORY ANALYSIS
    • 7.5.1.1 North America
      • 7.5.1.1.1 US
      • 7.5.1.1.2 Canada
    • 7.5.1.2 Europe
    • 7.5.1.3 Asia Pacific
      • 7.5.1.3.1 Japan
      • 7.5.1.3.2 China
      • 7.5.1.3.3 India

8 PCR TECHNOLOGIES MARKET, BY PRODUCT

• 8.1 INTRODUCTION
• 8.2 REAGENTS AND CONSUMABLES
  • 8.2.1 INCREASING USE OF DPCR-BASED ANALYTICAL PROCEDURES IN GENETIC RESEARCH AND FORENSICS TO DRIVE MARKET
• 8.3 INSTRUMENTS
  • 8.3.1 RISING AVAILABILITY OF TECHNOLOGICALLY ADVANCED AND INNOVATIVE PCR INSTRUMENTS TO FUEL MARKET GROWTH
• 8.4 SOFTWARE AND SERVICES
  • 8.4.1 GROWING DEMAND FOR SPECIALIZED PCR ANALYSIS SOFTWARE IN ONCOLOGY STUDIES AND FORENSICS TO SPUR MARKET GROWTH

9 PCR TECHNOLOGIES MARKET, BY TECHNIQUE

• 9.1 INTRODUCTION
• 9.2 REAL-TIME PCR
  • 9.2.1 RISING ADOPTION OF REAL-TIME PCR AMONG RESEARCHERS AND HEALTHCARE PROFESSIONALS TO PROPEL MARKET GROWTH
• 9.3 CONVENTIONAL PCR
  • 9.3.1 COST-EFFECTIVENESS AND EASE OF USAGE IN ROUTINE CLONING, GENOTYPING, AND MUTATION ANALYSIS TO FUEL MARKET GROWTH
• 9.4 DIGITAL PCR
  • 9.4.1 FASTER RESULTS WITH LOWER MARGIN ERRORS TO DRIVE ADOPTION
• 9.5 REVERSE TRANSCRIPTION PCR
  • 9.5.1 HIGHER SENSITIVITY FOR MEASURING CHANGES IN GENE EXPRESSION TO AUGMENT MARKET GROWTH
• 9.6 HOT-START PCR
  • 9.6.1 BETTER REACTION SPECIFICITY WITH LOWER ERROR RATES TO FAVOR MARKET GROWTH
• 9.7 MULTIPLEX PCR
  • 9.7.1 COST-EFFECTIVENESS AND HIGH THROUGHPUT TO AID MARKET GROWTH
• 9.8 OTHER PCR TECHNIQUES

10 PCR TECHNOLOGIES MARKET, BY APPLICATION

• 10.1 INTRODUCTION
• 10.2 DIAGNOSTIC APPLICATIONS
  • 10.2.1 UNAVAILABILITY OF REIMBURSEMENTS FOR CLINICAL DIAGNOSTIC TESTS TO LIMIT MARKET GROWTH
• 10.3 GENOTYPING
  • 10.3.1 LARGE TARGET PATIENT POPULATION FOR CANCER DIAGNOSIS TO AUGMENT MARKET GROWTH
• 10.4 NUCLEIC ACID DETECTION
  • 10.4.1 RISING PREVALENCE OF INFECTIOUS DISEASES TO BOOST MARKET GROWTH
• 10.5 GENE EXPRESSION ANALYSIS
  • 10.5.1 INCREASED R&D FUNDING AND GRANTS FOR PCR TO FAVOR MARKET GROWTH
• 10.6 NUCLEIC ACID SYNTHESIS
  • 10.6.1 INCREASED FOCUS ON PERSONALIZED AND PRECISE MEDICINES TO SUPPORT MARKET GROWTH
• 10.7 GENETIC SEQUENCING
  • 10.7.1 TECHNOLOGICAL IMPROVEMENTS AND REDUCED COSTS OF SEQUENCING TO FUEL MARKET GROWTH
• 10.8 ENVIRONMENTAL APPLICATIONS
  • 10.8.1 STRICT GOVERNMENT ENVIRONMENTAL POLICIES TO PROMOTE USE OF PCR
• 10.9 STANDARD VALIDATION/VERIFICATION
  • 10.9.1 NEED FOR REGIONAL/GLOBAL VALIDATION FOR COMMERCIAL/NON-COMMERCIAL GUIDELINE FRAMING TO DRIVE MARKET
• 10.10 OTHER APPLICATIONS

11 PCR TECHNOLOGIES MARKET, BY END USER

• 11.1 INTRODUCTION
• 11.2 HOSPITAL LABORATORIES
  • 11.2.1 RISING PUBLIC AWARENESS OF ROUTINE CHECKUPS TO SUPPORT MARKET GROWTH
• 11.3 DIAGNOSTIC LABORATORIES
  • 11.3.1 ESTABLISHMENT OF INDEPENDENT SPECIALIZED DIAGNOSTIC LABORATORIES TO PROPEL MARKET GROWTH
• 11.4 ACADEMIC AND GOVERNMENT ORGANIZATIONS
  • 11.4.1 INCREASED GOVERNMENT SUPPORT FOR GENOME-BASED RESEARCH TO DRIVE MARKET
• 11.5 PHARMA-BIOTECH COMPANIES
  • 11.5.1 INCREASING R&D INITIATIVES BY PHARMA-BIOTECH COMPANIES TO DRIVE ADOPTION OF PCR TECHNOLOGIES
• 11.6 OTHER END USERS

12 PCR TECHNOLOGIES MARKET, BY REGION

• 12.1 INTRODUCTION
• 12.2 NORTH AMERICA
  • 12.2.1 US
    • 12.2.1.1 US to dominate North American PCR technologies market during study period
  • 12.2.2 CANADA
    • 12.2.2.1 Supportive government initiatives for genomics research to aid market growth
• 12.3 EUROPE
  • 12.3.1 GERMANY
    • 12.3.1.1 Presence of well-established pharmaceutical and R&D industry to augment market growth
  • 12.3.2 FRANCE
    • 12.3.2.1 Increasing investments in life science R&D for infrastructural development to favor market growth
  • 12.3.3 UK
    • 12.3.3.1 Rising acceptance of genome-based diagnosis by clinicians and healthcare professionals to spur market growth
  • 12.3.4 ITALY
    • 12.3.4.1 Supportive government policies and high healthcare expenditure to boost market growth
  • 12.3.5 SPAIN
    • 12.3.5.1 Increasing funding for life science research and pharmaceutical drug development to boost market growth
  • 12.3.6 REST OF EUROPE
• 12.4 ASIA PACIFIC
  • 12.4.1 CHINA
    • 12.4.1.1 Improved public access to modern healthcare facilities and advanced genomics research to fuel market growth
  • 12.4.2 JAPAN
    • 12.4.2.1 Well-established healthcare infrastructure and advanced cancer research activities to support market growth
  • 12.4.3 INDIA
    • 12.4.3.1 Presence of large target patient population and high government healthcare expenditure to support market growth
  • 12.4.4 AUSTRALIA
    • 12.4.4.1 High healthcare expenditure to drive adoption of advanced PCR technologies
  • 12.4.5 SOUTH KOREA
    • 12.4.5.1 Improved medical tourism and prevalence of chronic diseases to propel market growth
  • 12.4.6 REST OF ASIA PACIFIC
• 12.5 LATIN AMERICA
  • 12.5.1 BRAZIL
    • 12.5.1.1 Growing focus on proteomics and genomics research to drive market
  • 12.5.2 MEXICO
    • 12.5.2.1 Favorable trade agreements to support imports and improve accessibility to PCR instruments
  • 12.5.3 REST OF LATIN AMERICA
• 12.6 MIDDLE EAST & AFRICA
  • 12.6.1 GCC COUNTRIES
    • 12.6.1.1 Advancements in healthcare infrastructure and increased focus on personalized medicines to fuel market growth
  • 12.6.2 REST OF MIDDLE EAST & AFRICA

13 COMPETITIVE LANDSCAPE

• 13.1 INTRODUCTION
• 13.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PCR TECHNOLOGIES MARKET
• 13.3 REVENUE ANALYSIS, 2022-2025
• 13.4 MARKET SHARE ANALYSIS, 2025
  • 13.4.1 PCR INSTRUMENTS MARKET SHARE, BY KEY PLAYER, 2025
  • 13.4.2 PCR REAGENTS AND CONSUMABLES MARKET SHARE, BY KEY PLAYER, 2025
  • 13.4.3 GLOBAL PCR SOFTWARE AND SERVICES MARKET SHARE, BY KEY PLAYER, 2025
• 13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
  • 13.5.1 STARS
  • 13.5.2 EMERGING LEADERS
  • 13.5.3 PERVASIVE PLAYERS
  • 13.5.4 PARTICIPANTS
  • 13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
    • 13.5.5.1 Company footprint
    • 13.5.5.2 Product footprint
    • 13.5.5.3 Application footprint
    • 13.5.5.4 Technique footprint
    • 13.5.5.5 End user footprint
    • 13.5.5.6 Region footprint
• 13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
  • 13.6.1 PROGRESSIVE COMPANIES
  • 13.6.2 RESPONSIVE COMPANIES
  • 13.6.3 DYNAMIC COMPANIES
  • 13.6.4 STARTING BLOCKS
  • 13.6.5 COMPANY BENCHMARKING: STARTUPS/SMES, 2025
    • 13.6.5.1 Detailed list of key startups/SMEs players
    • 13.6.5.2 Competitive benchmarking of key startups/SMEs
• 13.7 COMPANY VALUATION AND FINANCIAL METRICS, 2025
• 13.8 PRODUCT/BRAND COMPARISON
• 13.9 COMPETITIVE SCENARIO
  • 13.9.1 PRODUCT LAUNCHES AND APPROVALS
  • 13.9.2 DEALS
  • 13.9.3 EXPANSIONS

14 COMPANY PROFILES

• 14.1 KEY PLAYERS
  • 14.1.1 THERMO FISHER SCIENTIFIC INC.
    • 14.1.1.1 Business overview
    • 14.1.1.2 Products/Services/Solutions offered
    • 14.1.1.3 Recent developments
      • 14.1.1.3.1 Product launches and approvals
      • 14.1.1.3.2 Deals
    • 14.1.1.4 MnM view
      • 14.1.1.4.1 Key strengths
      • 14.1.1.4.2 Strategic choices
      • 14.1.1.4.3 Weaknesses and competitive threats
  • 14.1.2 F. HOFFMANN-LA ROCHE LTD.
    • 14.1.2.1 Business overview
    • 14.1.2.2 Products/Services/Solutions offered
    • 14.1.2.3 Recent developments
      • 14.1.2.3.1 Product launches and approvals
      • 14.1.2.3.2 Deals
    • 14.1.2.4 MnM view
      • 14.1.2.4.1 Key strengths
      • 14.1.2.4.2 Strategic choices
      • 14.1.2.4.3 Weaknesses and competitive threats
  • 14.1.3 AGILENT TECHNOLOGIES, INC.
    • 14.1.3.1 Business overview
    • 14.1.3.2 Products/Services/Solutions offered
    • 14.1.3.3 Recent developments
      • 14.1.3.3.1 Deals
      • 14.1.3.3.2 Other developments
    • 14.1.3.4 MnM view
      • 14.1.3.4.1 Key strengths
      • 14.1.3.4.2 Strategic choices
      • 14.1.3.4.3 Weaknesses and competitive threats
  • 14.1.4 BIO-RAD LABORATORIES, INC.
    • 14.1.4.1 Business overview
    • 14.1.4.2 Products/Services/Solutions offered
    • 14.1.4.3 Recent developments
      • 14.1.4.3.1 Product launches
      • 14.1.4.3.2 Deals
    • 14.1.4.4 MnM view
      • 14.1.4.4.1 Key strengths
      • 14.1.4.4.2 Strategic choices
      • 14.1.4.4.3 Weaknesses and competitive threats
  • 14.1.5 QIAGEN
    • 14.1.5.1 Business overview
    • 14.1.5.2 Products/Services/Solutions offered
    • 14.1.5.3 Recent developments
      • 14.1.5.3.1 Product launches and approvals
      • 14.1.5.3.2 Deals
      • 14.1.5.3.3 Expansions
    • 14.1.5.4 MnM view
      • 14.1.5.4.1 Key strengths
      • 14.1.5.4.2 Strategic choices
      • 14.1.5.4.3 Weaknesses and competitive threats
  • 14.1.6 DANAHER CORPORATION
    • 14.1.6.1 Business overview
    • 14.1.6.2 Products/Services/Solutions offered
    • 14.1.6.3 Recent developments
      • 14.1.6.3.1 Product approvals
      • 14.1.6.3.2 Deals
      • 14.1.6.3.3 Expansions
  • 14.1.7 BBOTT
    • 14.1.7.1 Business overview
    • 14.1.7.2 Products/Services/Solutions offered
    • 14.1.7.3 Recent developments
      • 14.1.7.3.1 Deals
  • 14.1.8 TAKARA BIO INC.
    • 14.1.8.1 Business overview
    • 14.1.8.2 Products/Services/Solutions offered
    • 14.1.8.3 Recent developments
      • 14.1.8.3.1 Product launches
      • 14.1.8.3.2 Deals
  • 14.1.9 ANALYTIK JENA GMBH+CO. KG
    • 14.1.9.1 Business overview
    • 14.1.9.2 Products/Services/Solutions offered
    • 14.1.9.3 Recent developments
      • 14.1.9.3.1 Product launches
      • 14.1.9.3.2 Deals
  • 14.1.10 EPPENDORF SE
    • 14.1.10.1 Business overview
    • 14.1.10.2 Products/Services/Solutions offered
    • 14.1.10.3 Recent developments
      • 14.1.10.3.1 Product launches and approvals
      • 14.1.10.3.2 Deals
  • 14.1.11 MERCK KGAA
    • 14.1.11.1 Business overview
    • 14.1.11.2 Products/Services/Solutions offered
      • 14.1.11.2.1 Deals
      • 14.1.11.2.2 Expansions
  • 14.1.12 BIONEER CORPORATION
    • 14.1.12.1 Business overview
    • 14.1.12.2 Products/Services/Solutions offered
    • 14.1.12.3 Recent developments
      • 14.1.12.3.1 Other developments
  • 14.1.13 REVVITY
    • 14.1.13.1 Business overview
    • 14.1.13.2 Products/Services/Solutions offered
    • 14.1.13.3 Recent developments
      • 14.1.13.3.1 Product launches
      • 14.1.13.3.2 Other developments
  • 14.1.14 BECTON, DICKINSON AND COMPANY
    • 14.1.14.1 Business overview
    • 14.1.14.2 Products/Services/Solutions offered
    • 14.1.14.3 Recent developments
      • 14.1.14.3.1 Product launches and approvals
      • 14.1.14.3.2 Deals
  • 14.1.15 BIOMERIEUX
    • 14.1.15.1 Business overview
    • 14.1.15.2 Products/Services/Solutions offered
    • 14.1.15.3 Recent developments
      • 14.1.15.3.1 Product launches and approvals
  • 14.1.16 STANDARD BIOTOOLS
    • 14.1.16.1 Business overview
    • 14.1.16.2 Products/Services/Solutions offered
  • 14.1.17 HOLOGIC, INC.
    • 14.1.17.1 Business overview
    • 14.1.17.2 Products/Services/Solutions offered
    • 14.1.17.3 Recent developments
      • 14.1.17.3.1 Product launches
  • 14.1.18 LONZA
    • 14.1.18.1 Business overview
    • 14.1.18.2 Products/Services/Solutions offered
  • 14.1.19 ILLUMINA, INC.
    • 14.1.19.1 Business overview
    • 14.1.19.2 Products/Services/Solutions offered
  • 14.1.20 SANSURE BIOTECH INC.
    • 14.1.20.1 Business overview
    • 14.1.20.2 Products/Services/Solutions offered
• 14.2 OTHER PLAYERS
  • 14.2.1 PROMEGA CORPORATION
  • 14.2.2 LIMING BIO
  • 14.2.3 TRANSGEN BIOTECH CO., LTD.
  • 14.2.4 DAAN GENE CO., LTD.
  • 14.2.5 BIOBASE GROUP
  • 14.2.6 NIPPON GENETICS EUROPE
  • 14.2.7 STILLA
  • 14.2.8 GENSCRIPT
  • 14.2.9 NEW ENGLAND BIOLABS

15 RESEARCH METHODOLOGY

• 15.1 RESEARCH DATA
• 15.2 RESEARCH DESIGN
  • 15.2.1 SECONDARY RESEARCH
    • 15.2.1.1 Key secondary sources
    • 15.2.1.2 Key objectives of secondary research
    • 15.2.1.3 Key data from secondary sources
  • 15.2.2 PRIMARY RESEARCH
    • 15.2.2.1 Key primary sources
    • 15.2.2.2 Key objectives of primary research
    • 15.2.2.3 Key industry insights
    • 15.2.2.4 Breakdown of primaries
• 15.3 MARKET SIZE ESTIMATION
  • 15.3.1 BOTTOM-UP APPROACH
    • 15.3.1.1 Company revenue estimation approach
    • 15.3.1.2 Customer-based market estimation
    • 15.3.1.3 Top-down approach
    • 15.3.1.4 Primary interviews
  • 15.3.2 GROWTH FORECAST
• 15.4 DATA TRIANGULATION
• 15.5 MARKET SHARE ASSESSMENT
• 15.6 STUDY ASSUMPTIONS
• 15.7 GROWTH ASSUMPTIONS
• 15.8 RISK ASSESSMENT
• 15.9 RESEARCH LIMITATIONS

16 APPENDIX

• 16.1 DISCUSSION GUIDE
• 16.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 16.3 CUSTOMIZATION OPTIONS
• 16.4 RELATED REPORTS
• 16.5 AUTHOR DETAILS